protein
| interacting with androgen receptor (AR) |
|
interacting with HTATIP, to regulate RCHY1 stability |
|
enhancing AR-mediated transcription with a dynamic pattern of recruitment to androgen response elements in the prostate-specific antigen (PSA) gene |
|
interaction with GORAB that enhances or represses the ubiquitin-protein ligase activity of RCHY1 |
|
interacting with TP53 (interacts with both N- and C-terminal domains of RCHY1) |
|
interacting with UBE2D2 |
|
interacting with MDM2 (capacity to negatively regulate TP53 through physical interaction and ubiquitin-mediated proteolysis independent of MDM2) |
|
AIG1 is a novel RCHY1-interacting protein, that activates the NFAT signaling pathway |
|
target of the TP53 tumor suppressor, monoubiquitinates POLH at one of multiple lysine residues |
|
promotes the proteasomal turnover of TP73 |
|
ubiquitination of TP73 mediated by RCHY1 represents an important pathway for controlling the suppressive function of TP73 |
|
MYC is a novel interacting protein for RCHY1 and RCHY1 mediates its polyubiquitylation and proteolysis |
|
RCHY1 interacts with CHEK2 and mediates its polyubiquitylation and proteasomal degradation |
|
HOXA2 interacts with the RING-finger type E3 ubiquitin ligase RCHY1 and induces its proteasomal degradation |
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in lung cancer, prostatic carcinoma, head and neck cancer | tumoral
|  
|  
| --over
|  
|
in lung tumorigenesis by reducing TP53 activity | tumoral
|  
|  
| --over
|  
|
in hepatocellular liver carcinoma (HCC) cell line, and is correlated with poor survival and prognostic in patients with HCC | |